Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.
作者信息
Cerhan James R, Link Brian K, Habermann Thomas M, Maurer Matthew J, Feldman Andrew L, Syrbu Sergei I, Thompson Carrie A, Farooq Umar, Novak Anne J, Slager Susan L, Allmer Cristine, Lunde Julianne J, Macon William R, Inwards David J, Johnston Patrick B, Micallef Ivana N M, Nowakowski Grzegorz S, Ansell Stephen M, Kay Neil E, Weiner George J, Witzig Thomas E
机构信息
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
出版信息
Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. doi: 10.1093/ije/dyx119.
Abstract
摘要
相似文献
1
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.队列简介：淋巴瘤卓越研究专项计划（SPORE）分子流行病学资源（MER）队列研究
Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. doi: 10.1093/ije/dyx119.
2
Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.蕈样肉芽肿和塞扎里综合征患者的继发性淋巴瘤及其他恶性肿瘤：基于人群和临床队列的证据
Arch Dermatol. 2007 Jan;143(1):45-50. doi: 10.1001/archderm.143.1.45.
3
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.被遗忘的老年人——过去 40 年原发性中枢神经系统淋巴瘤生存趋势的变化。
Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.
4
Primary Colorectal Lymphoma: Institutional Experience and Review of a National Database.原发性结直肠淋巴瘤：机构经验和国家数据库回顾。
Dis Colon Rectum. 2019 Oct;62(10):1167-1176. doi: 10.1097/DCR.0000000000001279.
5
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.早期事件状态可提示新诊断滤泡性淋巴瘤的后续预后。
Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492. Epub 2016 Sep 3.
6
Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.美国成人 T 细胞白血病/淋巴瘤的流行病学和生存趋势。
Cancer. 2020 Feb 1;126(3):567-574. doi: 10.1002/cncr.32556. Epub 2019 Nov 26.
7
A 10year cohort study of 175 primary gastrointestinal lymphoma cases in Thailand clinical features and outcomes in the immunochemotherapy era.泰国 175 例原发性胃肠道淋巴瘤 10 年队列研究：免疫化疗时代的临床特征和结局。
Hematology. 2021 Dec;26(1):249-255. doi: 10.1080/16078454.2021.1889160.
8
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.1975 - 1999年原发性中枢神经系统淋巴瘤的生存趋势：一项基于人群的分析。
Cancer. 2005 Dec 1;104(11):2466-72. doi: 10.1002/cncr.21481.
9
Lymphoma in acquired immunodeficiency syndrome.获得性免疫缺陷综合征中的淋巴瘤
Semin Oncol. 1990 Feb;17(1):104-12.
10
Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.自体造血细胞移植患者与侵袭性淋巴瘤非移植患者的长期健康相关生活质量：一项前瞻性队列分析。
JCO Oncol Pract. 2022 Jul;18(7):e1069-e1080. doi: 10.1200/OP.21.00694. Epub 2022 May 20.
引用本文的文献
1
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts.滤泡性淋巴瘤3B的亚组具有不同的预后：前瞻性多中心MER和LEO队列的结果
Blood Cancer J. 2025 Aug 8;15(1):134. doi: 10.1038/s41408-025-01347-0.
2
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.滤泡性淋巴瘤的偶然诊断与症状性诊断：早期检测的影响
Blood Cancer J. 2025 Jul 3;15(1):116. doi: 10.1038/s41408-025-01322-9.
3
Risk of lymphoid malignancy associated with cancer predisposition genes.与癌症易感性基因相关的淋巴恶性肿瘤风险。
Blood Cancer J. 2025 Apr 19;15(1):71. doi: 10.1038/s41408-025-01283-z.
4
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin.基于起源细胞定义的弥漫性大B细胞淋巴瘤亚型风险的病因异质性评估。
Cancer Epidemiol Biomarkers Prev. 2025 May 2;34(5):780-787. doi: 10.1158/1055-9965.EPI-24-1610.
5
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.弥漫性大 B 细胞淋巴瘤与原发性治疗抵抗相关的分子特征。
Hematol Oncol. 2025 Jan;43(1):e70006. doi: 10.1002/hon.70006.
6
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.伴有24个月无进展生存期的滤泡性淋巴瘤的治疗模式与结局：来自LEO联盟的分析
Blood Adv. 2025 Mar 11;9(5):1013-1023. doi: 10.1182/bloodadvances.2024014053.
7
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot.血浆甲基化DNA标志物在淋巴瘤检测中的发现、验证及临床预试验
Am J Hematol. 2025 Feb;100(2):218-228. doi: 10.1002/ajh.27533. Epub 2024 Nov 20.
8
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas.DEK 调节 B 细胞的增殖能力，并与低级别 B 细胞淋巴瘤的侵袭性疾病相关。
Blood Cancer J. 2024 Oct 9;14(1):172. doi: 10.1038/s41408-024-01145-0.
9
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.边缘区淋巴瘤的转化：一项前瞻性队列研究和文献荟萃分析的结果。
Blood Adv. 2024 Dec 10;8(23):5939-5948. doi: 10.1182/bloodadvances.2024013188.
10
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.弥漫性大B细胞淋巴瘤的转录组分类鉴定出一个具有可靶向的MYC失调的高危活化B细胞样亚群。
Nat Commun. 2024 Aug 8;15(1):6790. doi: 10.1038/s41467-024-50830-y.
本文引用的文献
1
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.早期事件状态可提示新诊断滤泡性淋巴瘤的后续预后。
Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492. Epub 2016 Sep 3.
2
Diffuse Large B-Cell Lymphoma Version 1.2016.弥漫性大 B 细胞淋巴瘤 1.2016 年版
J Natl Compr Canc Netw. 2016 Feb;14(2):196-231. doi: 10.6004/jnccn.2016.0023.
3
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
4
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤患者24个月无事件生存的个性化风险预测。
Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223. Epub 2015 Nov 26.
5
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.综合血清细胞因子分析确定白细胞介素-1受体拮抗剂（IL-1RA）和可溶性白细胞介素-2受体α（sIL-2Rα）为T细胞淋巴瘤无事件生存期的预测指标。
Ann Oncol. 2016 Jan;27(1):165-72. doi: 10.1093/annonc/mdv486. Epub 2015 Oct 20.
6
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.免疫化疗治疗弥漫性大B细胞淋巴瘤无事件生存期的全基因组关联研究
J Clin Oncol. 2015 Nov 20;33(33):3930-7. doi: 10.1200/JCO.2014.60.2573. Epub 2015 Oct 12.
7
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.全外显子组分析揭示了与免疫化疗治疗的弥漫性大B细胞淋巴瘤预后相关的新型体细胞基因组改变。
Blood Cancer J. 2015 Aug 28;5(8):e346. doi: 10.1038/bcj.2015.69.
8
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.弥漫性大B细胞淋巴瘤（DLBCL）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25. doi: 10.1093/annonc/mdv304.
9
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).现代转化型滤泡性淋巴瘤的结局：来自国家淋巴瘤关爱研究（NLCS）的报告。
Blood. 2015 Aug 13;126(7):851-7. doi: 10.1182/blood-2015-01-621375. Epub 2015 Jun 23.
10
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.BCL2 突变与滤泡性淋巴瘤的转化风险增加和生存时间缩短相关。
Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.
Zotero 插件